Glucose Meters in Pennsylvania

Conductive Technologies Inc. (CTI) is a contract manufacturer specializing in printed electronics and biosensors for the medical device and industrial markets. Founded in 1970 and based in York, Pennsylvania, CTI operates a 110,000 sq. ft. facility with approximately 61 employees and generates $15.4 million in annual revenue. The company holds FDA compliance and ISO 13485 (medical devices) and ISO 9001 certifications, supporting full medical device project development from conception through FDA clearance. CTI's core competencies include electrochemical sensors, biosensors, flexible circuits, and membrane switches. The company manufactures disposable glucose test strips, multiplexed point-of-care diagnostic sensors, wearable devices, and biochips/microfluidics. Manufacturing capabilities include precision laser ablation, fine-line screen printing, and flexible printed circuitry with diverse inks and materials. CTI offers design innovation, development services, and post-commercialization collaboration, particularly for next-generation disposable diagnostic biosensors and Phase Zero Sensors for early-stage biochemical assay development. The structured development process ensures products meet customer requirements and market competitiveness.

LifeScan is a global leader in glucose monitoring and diabetes management, serving more than 20 million consumers worldwide through its OneTouch® brand. The company develops and markets blood glucose meters, continuous glucose monitoring systems, mobile applications, and related digital health solutions for diabetes self-management. Product lines include the OneTouch Verio Flex® blood glucose meter paired with the OneTouch Reveal® mobile application, which provides real-world evidence of improved glycemic control. LifeScan recently announced a transformational partnership with i-SENS to launch a OneTouch® Continuous Glucose Monitoring System, expanding its portfolio into CGM technology. The company emphasizes patient-centric digital solutions and clinical validation; multiple peer-reviewed studies document clinically significant improvements in glycemic control across diverse patient populations using LifeScan's smart meters and mobile apps. LifeScan serves both individual consumers and healthcare systems, with a focus on Type 1 and Type 2 diabetes management. The company maintains a global presence and was recently recognized by the Princess Royal Training Awards (2024). Operations include manufacturing, digital partnerships, customer support, and clinical research capabilities. LifeScan emerged from financial restructuring in 2025 with renewed operational focus on innovation and market expansion.